Mycoplasma genitalium: An Emerging Cause of Pelvic Inflammatory Disease by Haggerty, Catherine L. & Taylor, Brandie D.
Hindawi Publishing Corporation
Infectious Diseases in Obstetrics and Gynecology
Volume 2011, Article ID 959816, 9 pages
doi:10.1155/2011/959816
Review Article
Mycoplasmagenitalium:A nEme rgingCauseo f
Pelvic Inﬂammatory Disease
Catherine L. Haggerty1 and Brandie D. Taylor2
1Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA
2Department of Epidemiology, Michigan State University, East Lansing, MI 48824, USA
Correspondence should be addressed to Catherine L. Haggerty, haggerty@pitt.edu
Received 14 June 2011; Revised 10 September 2011; Accepted 13 September 2011
Academic Editor: Thomas Cherpes
Copyright © 2011 C. L. Haggerty and B. D. Taylor. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Mycoplasma genitalium is a sexually transmitted pathogen that is increasingly identiﬁed among women with pelvic inﬂammatory
disease (PID). Although Chlamydia trachomatis and Neisseria gonorrhoeae frequently cause PID, up to 70% of cases have an
unidentiﬁed etiology. This paper summarizes evidence linking M. genitalium to PID and its long-term reproductive sequelae.
Several PCR studies have demonstrated that M. genitalium is associated with PID, independent of gonococcal and chlamydial
infection. Most have been cross-sectional, although one prospective investigation suggested that M. genitalium was associated with
over a thirteenfold risk of endometritis. Further, a nested case-control posttermination study demonstrated a sixfold increased
risk of PID among M. genitalium positive patients. Whether or not M. genitalium upper genital tract infection results in long-
term reproductive morbidity is unclear, although tubal factor infertility patients have been found to have elevated M. genitalium
antibodies. Several lines of evidence suggest that M. genitalium is likely resistant to many frequently used PID treatment regimens.
Correspondingly, M. genitalium has been associated with treatment failure following cefoxitin and doxycycline treatment for
clinically suspected PID. Collectively, strong evidence suggests that M. genitalium is associated with PID. Further study of M.
genitalium upper genital tract infection diagnosis, treatment and long-term sequelae is warranted.
1.Introduction
Mycoplasma genitalium is a genital tract microorganism [1,
2] identiﬁed in approximately 15 to 20% of young women
seen in some adolescent health centers, sexually transmitted
infection clinics, and emergency departments in the United
States [3–6]. Concordance of M. genitalium infection [1, 2, 7,
8]a sw e l la sM. genitalium sequence type [9] among sexual
partners suggests that this bacteria is sexually transmitted. In
some populations studied, infection with M. genitalium is as
common as Chlamydia trachomatis among high risk sexually
active women [3, 10] and women with clinically suspected
pelvic inﬂammatory disease (PID) [4]. As C. trachomatis
is the most common reportable bacterial infection in the
United States [11], M. genitalium is thus a relatively common
infection. M. genitalium has been associated with cervicitis
[2, 12–15] and may play a role in PID, the infection and
inﬂammation of a woman’s upper genital tract [16].
PID is frequent among women of childbearing age,
diagnosed in approximately 8% of US women and 15%
of Swedish women in their lifetime, with over one million
U.S. women treated annually [17–22]. Major reproductive
and gynecologic morbidities result from PID, including
infertility, ectopic pregnancy, chronic pelvic pain, and
recurrent PID [23]. Although PID has a polymicrobial
etiology, with C. trachomatis and/or N. gonorrhoeae isolated
from approximately one-third to one half of cases [5,
24–27], many PID cases have an unidentiﬁed etiology.
Although bacterial vaginosis-associated and mycoplasmal
organisms have been associated with PID [4–6, 13, 25,
27–32], independent of gonococcal and chlamydial infec-
tion [4, 28], less is known about the etiology, treatment,
and sequelae of nongonococcal, nonchlamydial PID. This
paper reviews recent evidence for the role of M. genital-
ium in PID and subsequent reproductive and gynecologic
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2.Mycoplasma genitalium Lower Genital
Tract Infection
M. genitalium was ﬁrst identiﬁed in the early 1980s
among men with nongonococcal urethritis [33]. Because the
microbe is extremely diﬃcult to culture, only with poly-
merase chain reaction (PCR) technology has research into
the pathogenicity of M. genitalium progressed. Numerous
studies have conﬁrmed the role of M. genitalium in acute
and chronic drug-resistant nongonococcal urethritis [34–
36]. In women, M. genitalium has been positively associ-
ated with cervical inﬂammation and clinically diagnosed
cervicitis, although variable case deﬁnitions of cervicitis are
responsible for some discrepancies in this literature [12].
As C. trachomatis is a common cause of cervicitis and thus
may confound this series of studies, some have excluded
patients testing positive for C. trachomatis or have adjusted
for it in multivariate analyses. The vast majority of these
have demonstrated an independent, signiﬁcant association
between M. genitalium and cervicitis [12].
3.Mycoplasma genitalium andPID
PID typically occurs as microorganisms ascend from the
lower genital tract and through the cervical os, infecting
the uterus, fallopian tubes, and ovaries. Thus, cervicitis is
a common antecedent of PID. Because M. genitalium is
associated with cervicitis [2, 13–15], it is reasonable that it
also causes nongonococcal, nonchlamydial PID. Indeed, this
organism induces salpingitis in monkeys [37, 38], has been
found to ascend from the lower to the upper genital tract in a
mouse model [39], causes morphologic changes in ciliated
fallopian tube cells in vitro [40], and has been detected
in fallopian tube tissue in a woman with salpingitis [41].
Further, M. genitalium has been shown to adhere to human
spermatozoa, and therefore may potentially be carried by
motile sperm to the female upper genital tract [42].
M. genitalium is detected by PCR frequently among
women with PID, with rates ranging from 13% to 16%
[4, 6, 43]. Several epidemiologic studies have associated M.
genitalium with clinically suspected PID, endometritis, and
adnexitis (see Table 1)[ 4, 6, 13, 32, 41, 43, 45]. In particular,
a handful of studies have examined the relationship between
M. genitalium identiﬁed by PCR and either histologically
conﬁrmed endometritis or salpingitis among a population
of women with clinically suspected PID [4, 6]. In a study
of 115 women presenting to a sexually transmitted disease
clinic in Nairobi, Kenya, women with histologically con-
ﬁrmed endometritis were signiﬁcantly more likely to have
M. genitalium identiﬁed by PCR from the cervix and/or
endometrium (16% versus 2%, P = 0.02) [6]. After
excluding women with gonococcal or chlamydial infection,
thisstudydemonstratedanindependentassociationbetween
M. genitalium and PID [6]. Similarly, in the PEACH study,
Haggerty et al. reported that 15% (88) of 586 women with
clinically suspected PID tested positive for M. genitalium in
the cervix and/or endometrium by PCR. These women were
more than twice as likely to have histologically conﬁrmed
endometritis at baseline (OR 2.6, 95% CI 1.5–4.6) as
compared to women without M. genitalium identiﬁed at
either site, and this relationship remained signiﬁcant after
adjustment for age, race, and gonococcal and chlamydial
infection (adjusted OR 2.0, 95% CI 1.0–4.2) [4].
A weakness of the above investigations and a problem
which challenges many PID studies are the lack of a true
comparison group without signs and symptoms of PID.
That is, the control groups were comprised of women with
clinically suspected PID who did not have histologically
conﬁrmed endometritis. In an attempt to overcome this
limitation, a few studies have been conducted with control
groups comprised of women without clinically suspected
PID. In a study of 53 patients with PID and 80 asymptomatic
pregnant women recruited from an obstetrics and gynecol-
ogy clinic, Uno et al. demonstrated a higher prevalence of
M. genitalium detected by PCR among the women with PID
as compared to controls (6% versus 0%) [13]. In another
study of 45 patients with clinically suspected PID and 37
control women undergoing tubal ligation, M. genitalium was
d e t e c t e db yP C Ri n1 3 %o fc a s e sv e r s u s0 %o fc o n t r o l s[ 43].
These studies collectively demonstrate a higher prevalence
of M. genitalium among PID patients as compared to
external controls, but are limited by the lack of upper genital
tract sampling. One study of 194 patients with clinically
suspected PID and 246 asymptomatic pregnant women
being screened for rubella compared the seroprevalence of
M. genitalium using a lipid-associated membrane protein-
enzyme immunoassay (LAMP-EIA) [44]. Before and after
adjustment for chlamydial antibodies, M. genitalium was
not associated with PID (OR 1.0, 95% CI 0.6–1.7). The
null association may be explained by the use of a serologic
marker of M. genitalium, which measures both acute and
past exposure. Thus, it may be that only current or recent
M. genitalium infection is associated with current PID.
The cross-sectional nature of most M. genitalium and
PID studies has made it diﬃcult to determine whether or
not the relationship is causal. However, there are a handful
of prospective studies which allow for temporal assessment.
WithinthePEACHcohort,Haggertyetal.demonstratedthat
the relationship between M. genitalium and endometritis
was independent and causal, since among women without
concurrent N. gonorrhoeae and/or C. trachomatis,ap o s i t i v e
endometrial PCR test for M. genitalium was associated with
over a thirteenfold risk of incident endometritis, assessed
histologically 30 days following a baseline evaluation of M.
genitalium (adjusted RR 13.4, 2.4–75.2) [4]. Similarly, in
a nested case-control study of 2079 women presenting for
pregnancy termination at Malmo University Hospital, M.
genitalium was signiﬁcantly associated with postabortal PID
(OR 6.3, 95% CI 1.6–25.2) [45]. Lastly, a study of 2378
sexually active female students participating in a chlamydia
screening trial in London reported a positive, nonsigniﬁcant
association between M. genitalium and subsequent PID (RR
2.4, 95% CI 0.7–7.5) [46]. There are several reasons why this
study’s ﬁndings are diﬀerent from those by Haggerty and
Bjartling. First, despite the large sample size, the study was
underpowered to detect a prospective association between
M. genitalium and PID. Second, PID was assessed largely byInfectious Diseases in Obstetrics and Gynecology 3
Table 1: Studies evaluating the relationship between M. genitalium and pelvic inﬂammatory disease.
Citation Sample size,
population, setting Study design
Methods:
M. genitalium test
PID diagnosis
Findings Validity
Uno et al. [13]
200 patients aged 19
to 49 years visiting
the OB Gyn
department of
Kizawa Memorial
Hospital and
Hayasaki Ladies
Clinic.
Cross-
sectional
M. genitalium:P C R
of endocervical
specimens.
PID: clinical criteria.
5.7% of PID patients
versus 0% of pregnant
controls tested positive
for M. genitalium
(P-value or OR not
reported, one patient
co-infected with C.
trachomatis).
Strengths: Control group
of patients without signs
and symptoms of PID.
Limitations: No
laparoscopic or histologic
conﬁrmation of PID.
Although C. trachomatis
was assessed, sample size
too small to determine
independent eﬀect of M.
genitalium
Cohen et al.
[6]
115 patients
presenting with
pelvic pain ≤ 14
days presenting to a
sexually transmitted
diseases clinic,
Nairobi, Kenya
between 2000–2003.
Cross-
sectional
M. genitalium: PCR
of cervical and
endometrial
samples.
PID: histologically
conﬁrmed
endometritis.
M. genitalium detected
in 16% of patients with
endometritis versus 2%
of patients without
endometritis
(P = 0.03).
M. genitalium
identiﬁed in the
endometrium was
associated with
endometritis after
excluding women with
gonococcal or
chlamydial infection
(P = 0.03, percentages
not presented in the
paper).
Strengths: PID deﬁned
histologically.
Adjustment for C.
trachomatis and N.
gonorrhoeae allows for
independent association
between M. genitalium
and PID to be examined.
Limitations: No control
group of women without
clinically suspected PID.
Cross-sectional design
does not allow for a
temporal association to
be proven
Simms et al.
[43]
45 patients with a
clinical diagnosis of
PID (ages 16–43)
and 37 patients
undergoing tubal
ligation (ages
21–45).
Case-control
study
M. genitalium: PCR
of endocervical
swabs.
PID: clinical criteria.
M. genitalium detected
in 13% of patients
versus 0% of controls.
Strengths: Control group
of patients without signs
and symptoms of PID
(although not conﬁrmed
histologically or
laparoscopically.
Limitations: No upper
genital tract specimens
collected.
PID was not conﬁrmed
laparoscopically or
histologically.
No adjustment for
confounders.
Cross-sectional design
does not allow for a
temporal association to
be proven.
Cohen et al.
[41]
123 women aged
18–40 with
laparoscopically
conﬁrmed PID
treated at Kenyatta
National Hospital,
2000–2003.
Cross-
sectional
study
M. genitalium:P C R
of cervical,
endometrial, and
fallopian tube
samples.
PID:
laparoscopically
diagnosed
salpingitis, graded as
mild, moderate, or
severe.
M. genitalium detected
in the fallopian tube of
one patient.
6% of women with
mild, 11% of women
with moderate, and 6%
of women with severe
salpingitis tested
positive for M.
genitalium in one or
more site.
Strengths: PID veriﬁed by
laparoscopy.
Limitations: No control
group of women without
PID.
Cross-sectional design
does not allow for a
temporal association to
be proven.4 Infectious Diseases in Obstetrics and Gynecology
Table 1: Continued.
Citation Sample size,
population, setting Study design
Methods:
M. genitalium test
PID diagnosis
Findings Validity
Jurstrand et al.
[44]
194 inpatients with
PID aged 15–50 and
83 inpatients with
ectopic pregnancy
(EP) aged 18–42
treated in the
OBGyn department
of ¨ Orebo University
Hospital, ¨ Orebo,
Sweden, 1984–1986.
246 healthy
pregnant women
being screened for
rubella were
matched to ectopic
pregnancy cases by
age.
Case control
study
M. genitalium:
antibodies assessed
using a
lipid-associated
membrane
protein-enzyme
immunoassay
(LAMP-EIA).
PID: clinical criteria.
M. genitalium and PID:
Crude OR 1.3
(0.7–2.2).
Adjusted OR 1.0
(0.6–1.7)
M. genitalium &E P :
Crude OR 1.3
(0.7–2.5).
Adjusted OR 1.0
(0.5–2.0).
(Adjusted for age and
C. trachomatis
antibodies.)
Strengths: LAMP-EIA
covers antigenic variation
of diﬀerent genotypes of
M. genitalium with no
cross-reactivity with
other Mycoplasma
species.
Limitations: PID not
laparoscopically or
histologically conﬁrmed.
Limited adjustment for
confounders.
Unable to determine
timing of M. genitalium
infection in relation to
the acute PID episode.
Haggerty et al.
[4]
682 women with
clinically suspected
PID aged 14–37
years recruited from
ER, OB/Gyn, STD
clinics, and private
practice from 13
U.S. urban clinical
sites, 1996–1999.
Prospective
M. genitalium: PCR
of cervical and
endometrial
samples.
PID: histologically
conﬁrmed
endometritis
assessed at baseline
and at a 30-day
follow-up clinic
visit.
Baseline comparison of
M. genitalium
(endometrium) and
endometritis:
Adjusted OR 3.0
(1.5–6.1).
Prospective evaluation
of baseline M.
genitalium and incident
endometritis (30-days
follow-up visit):
Adjusted RR 13.4
(2.4–75.2).
(Adjusted for age, race,
C. trachomatis,a n dN.
gonorrhoeae.)
Strengths: Large sample
size.
Histologic conﬁrmation
of PID.
Prospective analysis of
baseline M. genitalium
infection and incident
endometritis at the 30
day follow-up visit
supports a temporal
association.
Adjustment for C.
trachomatis and N.
gonorrhoeae allows for
independent association
between M. genitalium
and PID to be examined.
Limitations: No control
group of women without
clinically suspected PID
Bjartling et al.
[45]
2079 women aged
15–40 presenting for
termination of
pregnancy at Malm¨ o
University Hospital,
Sweden, 2003–2007.
Prospective
M. genitalium: PCR
of urine, vaginal,
and cervical
samples.
PID: clinical criteria.
M. genitalium &
posttermination PID:
Adjusted OR 6.3
(1.6–25.2).
(Adjusted for age and
C. trachomatis.)
Strengths: Prospective
design allows for
temporal inference.
Adjustment for C.
trachomatis allows for
independent association
between M. genitalium
and PID to be examined.
Limitations:
Generalizability limited
to post-abortal PID.
No upper genital tract
specimens tested.
PID not conﬁrmed
laparoscopically or
histologically.Infectious Diseases in Obstetrics and Gynecology 5
Table 1: Continued.
Citation Sample size,
population, setting Study design
Methods:
M. genitalium test
PID diagnosis
Findings Validity
Oakeshott et al.
[46]
2378 sexually active
female students
(mean age 21 years)
participating in a
chlamydia screening
trial, London,
2004–2006.
Prospective
M. genitalium:P C R
of self-collected
vaginal swabs.
PID: Self-reported
PID and PID
symptoms, and
medical
records/clinical
diagnosis for a
subset of women not
completing
follow-up
questionnaire,
assessed over 12
months.
M. genitalium &P I D :
RR 2.4 (0.7–7.5).
Strengths. Large sample
size.
Prospective design allows
a temporal relationship
to be explored.
Limitations: PID
diagnosis based on
self-report and limited
medical record/clinical
diagnosis; no
laparoscopic or histologic
conﬁrmation.
Asymptomatic PID not
captured.
Despite large sample, the
study was underpowered
to detect a prospective
association between M.
genitalium and PID.
Selection bias may have
caused an underestimate
of M. genitalium.
self-report and thus may suﬀer from misclassiﬁcation bias.
Further, asymptomatic PID could not be captured in this
study. Additional prospective studies with active surveillance
of PID using biologic markers are needed to fully understand
the relationship between M. genitalium and PID.
4.DoesM. genitalium Infection Result in
Long-Term Reproductive Morbidity?
PID may result in long-term reproductive sequelae, includ-
ing infertility, ectopic pregnancy, and chronic pelvic pain.
Evidence for this comes from the Lund, Sweden cohort
study (1960–1984) in which among 2,501 women with clini-
cally suspected PID, salpingitis veriﬁed by laparoscopy was
associated with infertility, ectopic pregnancy, recurrent PID,
and chronic pelvic pain [23, 47]. Additionally, a number of
retrospective case-control studies have shown that women
with tubal occlusion are more likely to bear chlamydial
or gonococcal antibodies, providing human evidence for
causal links between chlamydial PID, gonococcal PID, and
infertility [48–52].
W h e t h e ro rn o tM. genitalium upper genital tract infec-
tion can result in reproductive or gynecologic sequelae is
unclear. Like C. trachomatis, M. genitalium is often asymp-
tomatic [1], increasing the likelihood for “silent” PID and
its sequelae. Also parallel to studies of C. trachomatis, M.
genitalium antibodies have been identiﬁed more frequently
(22% versus 6%) among 132 women with tubal factor
infertilitycomparedto176womennontubalfactorinfertility
[53].InasubsequentserologicinvestigationofM.genitalium
and tubal factor infertility by the same investigator, 212
couplesattendingfertilityclinicswereexaminedandastrong
antibody response against M. genitalium or C. trachomatis,
but no sign of current or chronic infection, was found in
women with TFI, indicating that previous infections caused
by these microorganisms may have resulted in permanent
damage and occlusion of the fallopian tubes [54]. In another
study of 51 infertility patients and 23 healthy, fertile women,
M. genitalium was identiﬁed in the cervical canal by PCR
among 20% of cases versus 4% of controls (P = 0.16) [55].
In subgroup analyses, M. genitalium was found in 29% (7 of
24) women with idiopathic infertility, and the comparison
to controls was of borderline statistical signiﬁcance (P =
0.05). Although these relationships were not statistically
signiﬁcant, they suggest that current infection with M.
genitalium and/or permanent damage to the reproductive
tract caused by chronic infection with M. genitalium may
impair fertility. One study has examined the relationship
between M. genitalium and reproductive morbidity among
a population of women with PID. In an analysis of 586
women from the PEACH study presenting with signs and
symptoms of PID, Haggerty et al. reported that rates of
sequelae, including chronic pelvic pain (42%), infertility
(22%), and recurrent PID (31%), were high among women
testing positive for active endometrial M. genitalium by PCR
at baseline [4]. Although diﬀerences in rates of sequelae were
not signiﬁcantly diﬀerent between women testing positive
or negative for M. genitalium, there was a trend toward in-
creasedchronicpelvicpain,infertility,andrecurrentPIDand
decreased pregnancy and live birth following M. genitalium
infection. The rate of subsequent infertility among women
with active endometrial M. genitalium was approximately
twice as high as the rate reported from a study utilizing the6 Infectious Diseases in Obstetrics and Gynecology
2002NationalSurveyofFamilyGrowthdata[17],suggesting
that preservation of fertility may be suboptimal for women
with M. genitalium upper genital tract infection.
Data examining M. genitalium and other reproductive
consequences are sparse. One serologic case-control study
of 82 ectopic pregnancy cases and 246 healthy pregnancy
control women found no statistically signiﬁcant association
between ectopic pregnancy and M. genitalium antibod-
ies [44]. Nonsigniﬁcant trends suggesting an association
between M. genitalium and ectopic pregnancy were found
among a subgroup of women aged 18–30 (OR 2.0, P =
0.133) and among women testing negative for C. trachomatis
antibodies (OR 2.3, P = 0.161) [44]. It may be possible
that reduced power in these subset analyses limited the
ability to detect statistically signiﬁcant associations. Further
large prospective studies utilizing both serology and PCR
are needed to better understand the potential reproductive
sequelae of M. genitalium infection.
5. Symptoms of M. genitalium and
Implications for DelayedTreatment
Although some studies have linked M. genitalium to patho-
logic vaginal discharge [56] and urethritis [57], several have
reportedthatbothM.genitalium[7,58,59]andC.trachoma-
tis [60] are comparatively less symptomatic than gonococcal
infection [60]. Harboring an asymptomatic infection may
increase the likelihood for delayed care and development
of sequelae. In a study of 516 sexual dyads, although M.
genitalium was associated with urethral discharge in men,
no symptoms were diagnostic of infection in women [8].
In addition, M. genitalium was found to be common in
asymptomatic patients attending an STD clinic in the United
Kingdom [61].
Symptoms of PID vary by microbial pathogen. For ex-
ample, chlamydial salpingitis tends to exhibit more mild
symptoms than gonococcal PID, despite the fact that both
pathogens cause tubal damage [60]. Short et al. found that,
compared to women with gonococcal PID, those with M.
genitalium-associated PID were less likely to have elevated
markersofinﬂammation,cervicitis,elevatedvaginalpH,and
ah i g hp e l v i cp a i ns c o r e[ 58]. However, signs and symptoms
of PID were similar between women with C. trachomatis and
M. genitalium [58]. This may indicate that, among women
with PID, those infected with N. gonorrhoeae present with
moreovertandseveresymptoms,leadingtoearliertreatment
than women with C. trachomatis or M. genitalium [60].
Long time to treatment is a major concern, as a case-control
study nested within a landmark Scandinavian study found
that delaying care for 3 or more days signiﬁcantly increased
the risk of impaired fertility among 443 women with PID
[62]. In a more recent study of 298 women with histo-
logically conﬁrmed endometritis, those with C. trachomatis
monoinfection and M. genitalium monoinfection reported
waiting the longest time between onset of symptoms and
care seeking (12.3 and 10.9 days), while the shortest times
were among women with N. gonorrhoeae monoinfection (4.6
days) and coinfection with two or more pathogens (5.6 days)
[63]. Delayed treatment of PID for 14 days or more was
not signiﬁcantly associated with reproductive morbidity in
this study. However, rates of infertility, recurrent PID, and
chronic pelvic pain were high in this cohort (17%, 20%, and
36%). Collectively, these studies may suggest that women
with M. genitalium-associated PID may have low levels of
chronic inﬂammation that can lead to reproductive damage
before treatment.
6. Treatment of Upper GenitalTract
M. genitalium Infection
If women with M. genitalium upper genital tract infection
do seek care, they will likely be treated with one of the
currently recommended CDC treatment regimens for PID
including (1) oﬂoxacin, (2) levoﬂoxacin, (3) ceftriaxone
plus doxycycline, or (4) cefoxitin and probenecid plus
doxycycline;allwithoptionalmetronidazoleforfullcoverage
against anaerobes and BV [64]. However, some of these
regimens are ineﬀective for the treatment of M. genitalium.
In the PEACH study, Haggerty et al reported that persistence
of M. genitalium was very high among women treated with
cefoxitin and doxycycline for PID, with 44% of women with
baseline endometrial PCR-positive specimens testing posi-
tive again 30 days following treatment [4]. In contrast, only
2% to 4% of women in the PEACH study had persistent or
recurrent gonococcal or chlamydial cervicitis when retested
at 30 days [24]. Women with M. genitalium identiﬁed in the
endometrium by PCR at study enrollment were four times
as likely to experience persistent endometritis and over four
times as likely to experience treatment failure, deﬁned as the
presenceofbothendometritisandpelvicpain30daysfollow-
ing treatment for PID (adjusted RR 4.6, 95% CI 1.1–20.1)
[4]. Further, M. genitalium strains resistant to tetracycline
have been isolated [65], and M. genitalium is associated with
persistent nongonococcal urethritis among men treated with
tetracyclines [35, 59, 66–68]a n dl e v o ﬂ o x a c i n[ 69, 70]f o r
nongonococcal urethritis. Thus, even if women with active
M. genitalium upper genital tract infection seek treatment,
antibiotic resistance among M. genitalium strains may lead
to persistent or recurrent infection, resulting in chronic
inﬂammation and infection.
7. Conclusion
PID is a common disease among American women that
results in frequent, serious reproductive morbidity. Most
women with PID are treated with antibiotics directed toward
N. gonorrhoeae and/or C. trachomatis, despite the fact that
these bacterial pathogens account for only a third to a half
of PID cases. Although M. genitalium has recently been
recognized as a cause of nongonococcal, nonchlamydial
PID, little is known about the long-term prognosis of M.
genitalium upper genital tract infection.
Given the scarcity of information regarding the long-
term prognosis of women infected with M. genitalium, the
lack of routine testing for M. genitalium in clinical practice,
and the resistance of M. genitalium to a number of PIDInfectious Diseases in Obstetrics and Gynecology 7
treatment regimens, additional research on the relationships
between M. genitalium, PID, and long-term reproductive
sequelae is critically needed in order to shape screening
and treatment guidelines. The high rate of treatment failure
among women with clinically suspected PID testing positive
for M. genitalium emphasizes a need for PID antibiotic
regimens targeted toward M. genitalium, with the ultimate
goal to prevent reproductive and gynecologic morbidity. M.
genitalium has demonstrated susceptibility to macrolides,
with azithromycin being the most active, and variable resis-
tance to ﬂuroquinolones, including ciproﬂoxacin [36, 71].
However, it should be noted that M. genitalium azithromycin
resistance has recently been reported [72, 73]. A newer
quinolone, moxiﬂocacin, has recently been shown to exhibit
a high degree of activity against M. genitalium [74], and
this antibiotic has also been shown to be eﬀective for the
treatment of PID [75]. Although these promising therapies
warrant further study for the treatment of PID, no highly
sensitive test is widely used to diagnose M. genitalium in
clinical practice. Nucleic acid ampliﬁcation tests (NAATs)
have been developed and tested [76], and they may be
useful for the clinical detection of M. genitalium among
PID patients. Endocervical swabs collected from patients
with clinically suspected PID are already often tested for
gonococcal and chlamydial infection, and thus a NAAT for
M. genitalium could eﬃciently be added to this diagnostic
screening. M. genitalium screening among patients with
clinically suspected PID would allow clinicians to select
treatment regimens speciﬁc for mycoplasmal PID. Addition-
ally, commercially available testing is also critical for the
identiﬁcation and treatment of uncomplicated lower genital
tract M. genitalium infection, in order to prevent subsequent
PID and potential sequelae.
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